Collecting and analyzing eye fluid from children with retinoblastoma
Retinoblastoma Patient Clinical Database and Tissue Repository
Children's Hospital Los Angeles · NCT04959097
This study is trying to see if collecting eye fluid from children with retinoblastoma can help find important markers for better treatment and understanding of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 0 Years to 18 Years |
| Sex | All |
| Sponsor | Children's Hospital Los Angeles (other) |
| Locations | 9 sites (Phoenix, Arizona and 8 other locations) |
| Trial ID | NCT04959097 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on retinoblastoma, a primary eye cancer in infants and toddlers, by utilizing aqueous humor as a liquid biopsy to detect tumor-derived markers. The study aims to systematically record clinical data and collect biomaterials such as aqueous humor, blood, and saliva from patients diagnosed with unilateral or bilateral retinoblastoma. By correlating phenotypic and genotypic data, the research seeks to identify clinically relevant biomarkers that could improve prognostication and facilitate personalized treatment plans. This approach addresses the limitations of traditional diagnostic methods that require surgical removal of the eye.
Who should consider this trial
Good fit: Ideal candidates for this study are infants and children up to 18 years old diagnosed with unilateral or bilateral retinoblastoma.
Not a fit: Patients who are only referred for second opinions and not treated at Children's Hospital Los Angeles will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic capabilities and personalized treatment options for children with retinoblastoma.
How similar studies have performed: While the use of aqueous humor as a liquid biopsy is a novel approach in retinoblastoma, similar methodologies in other cancers have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients, age 0 days to 18 years, with a diagnosis unilateral or bilateral retinoblastoma (RB) seen at CHLA (Children's Hospital Los Angeles). Exclusion Criteria: * Patients referred for second opinions only and not treated at CHLA for any reason.
Where this trial is running
Phoenix, Arizona and 8 other locations
- Phoenix Children's Hospital — Phoenix, Arizona, United States (RECRUITING)
- Children's Hospital Los Angeles — Los Angeles, California, United States (RECRUITING)
- Emory University Children's Healthcare of ATL — Atlanta, Georgia, United States (RECRUITING)
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States (RECRUITING)
- Oregon Health & Science University: Casey Eye Institute — Portland, Oregon, United States (RECRUITING)
- Wills Eye Institute — Philadelphia, Pennsylvania, United States (RECRUITING)
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States (RECRUITING)
- Seattle Children's Hospital; University of Washington — Seattle, Washington, United States (RECRUITING)
- The Hospital for Sick Children (Toronto SickKids) — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Principal investigator: Jesse L Berry, MD — Children's Hospital Los Angeles
- Study coordinator: Jesse L Berry, MD
- Email: jberry@chla.usc.edu
- Phone: 323-361-4510
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Retinoblastoma, Retinoblastoma Bilateral, Retinoblastoma Unilateral, RB, Ocular oncology, Aqueous humor